Introduction: Type-2 diabetes mellitus (T2DM)
INTRODUCTION
Guidelines from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) note that most patients with long-standing type 2 diabetes mellitus (T2DM) will need insulin at some point during their treatment [1] . Although the long-acting insulin analogs glargine and detemir improve glycemic control with a low risk of hypoglycemia in patients with T2DM [2] , initiation of insulin treatment is often delayed [3] .
Many studies have been conducted to examine the initiation of insulin glargine and insulin detemir among T2DM patients. A 52-week, open-label study compared outcomes in patients with T2DM treated with insulin glargine or insulin detemir as part of a basalbolus regimen (n = 319) [4] . Both insulin glargine and insulin detemir improved glycemic control, with similar overall effects in blood sugar control and low incidence of hypoglycemia for both. A Cochrane Database Review comparing insulin glargine and insulin detemir in randomized clinical trials likewise concluded that there were no differences in glycemic control between these two insulins, although twice-daily dosing and higher doses were more often needed with insulin detemir than with insulin glargine [5] . In addition, the ''Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes'' trial (EFFICACY: NCT00909480)-investigating the once-daily dosing of basal insulin as add-on to metformin over 26 weeks-showed that, while both improved glycemic control when added to metformin, the use of insulin glargine resulted in greater reductions in glycated hemoglobin (HbA 1c ) as compared with insulin detemir [6] .
In addition to these clinical studies, a few studies have also been conducted to examine the effects of these long-acting insulin analogs in a real-world setting. These real-world studies have reported somewhat conflicting data. Xie et al., for example, reported that patients initiating insulin glargine were more likely to persist with and adhere to treatment, and to show better glycemic control and similar overall hypoglycemia rate with no increase in healthcare costs [7] or weight change [8] , compared with those initiating insulin detemir. In contrast, a study of 306 patients enrolled in a large United States (US) managed care organization found that glycemic control after 180 days was similar for insulin glargine and insulin detemir [9] . In addition, McAdamMarx et al. reported that patients with T2DM
initiating insulin detemir were 30% less likely to gain 0.9 kg or more in body weight, with no significant difference in HbA 1c values, compared with insulin glargine [10] . Although there is much evidence available on the initiation of basal analog insulins, very few studies have investigated the effects of switching from one basal insulin to another.
Where studies have been conducted, their results have been conflicting. In a randomized double-blind crossover study in patients with T2DM, King et al. reported that once-daily dosing of insulin detemir and insulin glargine provided similar 24-h glycemic control [11] . However, this was a study of short duration and with only 36 patients. The ''Predictable Results and Experience in Diabetes through Intensification and Control to Target: an
International
Variability Evaluation'' (PREDICTIVE: NCT00659295) study was an observational study designed to evaluate switching from insulin glargine to insulin detemir (primarily with respect to adverse events) in patients with type 1 or T2DM [12] . In a European cohort of patients (n = 777) in the PREDICTIVE study, there were significant improvements in HbA 1c with fewer hypoglycemic events after switching to insulin detemir [13] . Using the framework of costeffectiveness analysis, an Asian study based on data from a Korean cohort of the PREDICTIVE study reported reduced total diabetes care costs and increased life expectancy of 0.06 years after switching from insulin glargine to insulin detemir [14] . A small retrospective study recently evaluated outcomes in patients (n = 10 with type 1 diabetes and n = 21 with T2DM) switching from insulin glargine to insulin detemir due to changes in Medicaid formulary coverage [15] . Among patients with T2DM, both insulin dose and the proportion of patients needing twice-daily dosing were significantly higher after switching to insulin detemir. Despite 33% higher daily dosing after switching to insulin detemir, HbA 1c levels were not improved compared with insulin glargine. More recently, the ''Retrospective Evaluation of a Long-acting Insulin Switch on Hemoglobin HbA 1c '' (RELISH) study found that HbA 1c levels increased significantly after patients converted from insulin glargine to insulin detemir, with no change in the proportion of patients achieving a goal of HbA 1c \7.0% [16] .
Furthermore, 22% of patients (9/41) switched from insulin detemir back to insulin glargine during the RELISH study. No published study examined switching from insulin detemir to insulin glargine.
Designed to expand upon these earlier reports, the current study investigated realworld outcomes among patients with T2DM switching basal insulin analogs, either from insulin glargine to insulin detemir or from insulin detemir to insulin glargine, by evaluating two large independent national US databases consisting of commercially insured and Medicare populations. [17] were included in the current analysis. Patients were further required to be C18 years of age, to have had continuous pharmacy and medical benefit coverage for C6 months before the index date (baseline) and for C12 months after the index date (follow-up), and to have had C1 HbA 1c test result obtained during the baseline period (within 6-month period before the index date until 15 days after the index date).
METHODS
Two cohorts were identified for the analyses in this study. Cohort 1 included patients who were treated with insulin glargine and subsequently either switched to insulin detemir (DET-S) or remained on insulin glargine (GLA-C). For the DET-S group, the index date is the initial switching date to detemir. The GLA-C group consisted of patients with C3 prescription drug claims for insulin glargine and no claims for insulin detemir, and their index date was chosen as a randomly selected date between the third and last insulin glargine claims dates. For both groups, patients were required to have at least one pharmacy claim for insulin glargine in each quarter during the baseline period, but not for premix or other basal insulin. Similarly, Cohort 2 included patients treated with insulin detemir and who subsequently either switched to insulin glargine (GLA-S) or remained on insulin detemir (DET-C). For the GLA-S group, the index date is the initial switching date to glargine. The DET-C group consisted of patients with C3 prescription drug claims for insulin detemir and no claims for insulin glargine, and their index date was chosen as a randomly selected date between the third and last insulin detemir claims dates. For both groups, patients were required to have at least one insulin detemir claim with each quarter, but no pharmacy claims for premix or other basal insulin during the baseline period. categories, all-cause and diabetes-related utilizations and costs, diabetes education and initiation device. The nearest neighbor PSM technique was used. Propensity scores were estimated by unconditional logistic regression analyses that incorporated potential predictors of therapy as independent variables in the regression and group status (e.g., DET-S vs GLA-C) as the outcome. In Cohort 1, a 1 up to 5 ratio was applied to DET-S and GLA-C patients. This was done separately for the IMPACT Ò and Humana Ò databases. For Cohort 2, a 1 up to 2 ratio was applied to DET-C and GLA-S patients, with the two independent databases being pooled together. These ratios and matchings were chosen because our preliminary analysis revealed a prescription imbalance, with significantly more eligible patients in the insulin glargine group when compared with the insulin detemir group, and a much lower number of patients in the switcher group as compared to the continuers group.
Assessments
Additionally, one-to-many matching has previously been validated as a method to increase precision in cohort studies when compared with one-to-one matching, and has also been supported in a recent review assessing the quality of statistical methodologies in matched case-control studies [25, 26] . Matching was implemented without replacement and any patient without at least one match was excluded from the analysis.
Between-group covariate balance was evaluated using descriptive t tests and v 2 tests (with corresponding P values) and standardized differences, where a standardized difference \10 indicated adequate balance [27] .
All analyses were performed using the intention-to-treat (ITT) approach on the matched patients. Due to the study design, DET-C or GLA-C patients could not, respectively, switch to insulin glargine or detemir during the follow-up period. However, GLA-S and DET-S patients were able to switch back to insulin detemir or glargine during the follow-up period. value dated after the first-quarter of the 1-year follow-up was used. A sensitivity analysis was conducted using 1:1 PSM between DET-S and GLA-C patients in Cohort 1 and between GLA-S and DET-C patients in Cohort 2.
All analyses were conducted using SAS 9.3 statistical software (SAS Institute Inc., Cary, USA).
This article does not contain any new studies with human or animal subjects performed by any of the authors.
RESULTS
A total of 13,882 eligible US patients were Table 1 ).
After PSM, most of the eligible switcher patients were matched to the continuer patients with similar baseline demographic, clinical, and economic characteristics. Standardized differences between groups were all \10.
In Cohort 1, the final study population included 792 DET-S patients and 3,930 GLA-C patients (IMPACT Ò : n = 536 DET-S matched to n = 2,668 GLA-C, mean age 54 years old, 47.2%
female, baseline HbA 1c 8.6%; Humana Ò : n = 256 DET-S matched to n = 1,262 GLA-C, mean age 72.9 years old, 55% female, baseline HbA 1c 8.2%; Table 1 ); patients in the Humana Ò database were older due to the fact that they HbA 1c glycated hemoglobin, DET-C patients continuing on insulin detemir, DET-S patients switching from insulin glargine to insulin detemir, GLA-C patients continuing on insulin glargine, GLA-S patients switching from insulin detemir to insulin glargine, T2DM type 2 diabetes mellitus Table 1 continued 8 .94% (n = 419 GLA-S matched to n = 780 DET-C, Table 1 ).
Insulin Utilization
During the 1-year follow-up period, in Cohort 1, patients switching from insulin glargine to insulin detemir, compared with patients continuing on insulin glargine, showed significantly lower rates of index basal insulin treatment persistence, shorter duration of persistence (Fig. 2a, b ) and lower rate of adherence (Fig. 3a, b) . These findings were consistent in both commercially insured IMPACT Ò population, and Medicare-insured Humana Ò elderly population. In contrast, in Cohort 2, GLA-S patients, as compared with DET-C patients, showed numerically, but not statistically significantly, higher index basal insulin treatment persistence (Fig. 2a, b) , and significantly higher rates of treatment adherence (Fig. 3a, b) .
The DACON was similar for DET-S and GLA-C patients (Fig. 4) . During the follow-up, RAI utilization was significantly lower among GLA-C patients versus DET-S in Cohort 1, but similar between the GLA-S and DET-C groups in Cohort 2 ( 
Clinical Outcomes
At the end of the follow-up year, in Cohort 1, mean HbA 1c was significantly higher among Table 1 continued 
SD standard deviation
DET-S patients compared with GLA-C patients (Fig. 6a) , and the mean change in HbA 1c from baseline was lower in the DET-S group than GLA-C group (only statistically significant in the IMPACT Ò database) (Fig. 6b) . Significantly more GLA-C patients achieved a target . DET-C patients continuing on insulin detemir, DET-S patients switching from insulin glargine to insulin detemir, GLA-C patients continuing on insulin glargine, GLA-S patients switching from insulin detemir to insulin glargine HbA 1c \7.0% in the Humana Ò group and a target HbA 1c \8.0% in both the IMPACT Ò and Humana Ò groups (Fig. 6c) .
In Cohort 2, although mean HbA 1c was not significantly different at the end of follow-up (Fig. 6a) , a greater reduction from baseline in Fig. 3 Follow-up treatment adherence: the non-adjusted and adjusted MPRs for insulin switchers and insulin continuers (a), and the percentage of patients achieving non-adjusted and adjusted MPRs C0.8 for insulin switchers and insulin continuers (b). DET-C patients continuing on insulin detemir, DET-S patients switching from insulin glargine to insulin detemir, GLA-C patients continuing on insulin glargine, GLA-S patients switching from insulin detemir to insulin glargine, MPR medication possession ratio Fig. 4 Follow-up DACON for insulin switchers and insulin continuers. DACON daily average consumption, DET-C patients continuing on insulin detemir, DET-S patients switching from insulin glargine to insulin detemir, GLA-C patients continuing on insulin glargine, GLA-S patients switching from insulin detemir to insulin glargine Follow-up RAI use of insulin switchers and insulin continuers. DET-C patients continuing on insulin detemir, DET-S patients switching from insulin glargine to insulin detemir, GLA-C patients continuing on insulin glargine, GLA-S patients switching from insulin detemir to insulin glargine, RAI rapid-acting insulin HbA 1c value was achieved among GLA-S patients when compared with DET-C patients (Fig. 6b) . Additionally, in the GLA-S group, at the end of 1-year follow-up, compared with those patients who remained on insulin glargine, those who restarted insulin detemir had higher HbA 1c (8.86% vs 8.23%, P = 0.0539) and lower HbA 1c reduction from baseline (-0.10% vs -0.81%; P = 0.0172). More patients in the GLA-S group achieved HbA 1c goals during follow-up than did those in the DET-C group (Fig. 6c) .
Although for Cohort 1 overall hypoglycemia prevalence rates were significantly higher for GLA-C in the Humana Ò database, overall both prevalence and event rates for Cohort 1 and 2 were similar between switchers and continuers, as
were severe hospital/ED-related hypoglycemia rates ( Table 2 ). detemir, DET-S patients switching from insulin glargine to insulin detemir, GLA-C patients continuing on insulin glargine, GLA-S patients switching from insulin detemir to insulin glargine
Economic Outcomes
Overall healthcare costs were similar across all four treatment cohorts (Table 3) . Although healthcare utilization did not differ according to treatment in Cohort 1, DET-S patients had significantly higher diabetes drug (P\0.0001) and diabetes supply costs (P = 0.0006) than GLA-C patients in the IMPACT Ò cohort; while in the Humana Ò cohort only diabetes drug costs were significantly higher for DET-S patients than for GLA-C patients (P = 0.0368; Table 3 ).
Total healthcare expenditure was $21,845 in the DET-C cohort and $24,417 in the GLA-S cohort and total expenditure for diabetesrelated healthcare was $10,293 and $10,619, respectively. These differences were not statistically significant.
Sensitivity Analysis
For index basal insulin treatment persistence, 
DISCUSSION
This real-world US study investigated the effects of switching from insulin glargine to insulin detemir (Cohort 1) or from insulin detemir to insulin glargine (Cohort 2), compared with not switching and remaining on baseline treatment. Table 2 1-Year follow-up hypoglycemia DET-C patients continuing on insulin detemir, DET-S patients switching from insulin glargine to insulin detemir, ED emergency department, GLA-C patients continuing on insulin glargine, GLA-S patients switching from insulin detemir to insulin glargine, SD standard deviation Table 3 1-Year follow-up economic outcomes DET-C patients continuing on insulin detemir, DET-S patients switching from insulin glargine to insulin detemir, ED emergency department, GLA-C patients continuing on insulin glargine, GLA-S patients switching from insulin detemir to insulin glargine,
Rx prescription drug
These data support previously published studies that show a low incidence of hypoglycemia among patients with T2DM treated with either insulin glargine or insulin detemir [4, 5, 15] . Similar to the PREDICTIVE trial [13] , the prevalence rate of hypoglycemia was lower after switching from insulin glargine to insulin detemir in the Medicare cohort in our study; however, the event rates were similar in both groups. No difference in hypoglycemia was observed in the commercially insured IMPACT Ò population. In contrast to previously published studies showing that insulin dose was typically higher with insulin detemir than insulin glargine [5, 15, 28] , it was similar among the matched GLA-C and DET-S patients based on the DACON estimate from the pharmacy claims data. In our study, however, DET-S patients had a much higher rate of RAI use than did GLA-C patients. Although dosing frequency information was not available for our data analysis, existing literature suggests that insulin detemir is more likely to be dosed more frequently than insulin glargine [15, 29] . Both higher twice-daily use and RAI use may explain the lower persistence and adherence rates and higher diabetes drug and supply costs in the DET-S group. and all-cause mortality [1] . The improvements in glycemic control observed in the current study conflict with results from the PREDICTIVE trial [13, 14] but are consistent with those from two US studies [15, 16] . In our study, the treatment persistence rate was significantly higher in the GLA-C group and medication adherence was significantly higher among GLA-S patients.
Importantly, a positive association between HbA 1c reduction and treatment persistence among T2DM patients receiving insulin therapy has previously been shown [7] . Also, similar to the results from the RELISH study [16] , a significant portion of DET-S patients restarted insulin glargine after switching to insulin detemir. Additionally, patients with randomly assigned index dates may have differed from other patients in their unmeasured treatment needs and willingness to engage in certain treatment decisions [32] . The direction of the overall bias is hard to estimate due to these opposing possible sources of bias, but is believed to affect both GLA-C and DET-C patients in the current study. Data within claims databases may have inaccuracies introduced through coding errors that could not be identified because of a lack of access to additional patient records. Insulin persistence and adherence and daily dose were based on pharmacy claims data, which reflect prescription filling and do not verify that filled prescriptions were taken as directed, and also cannot account for amount of wastage. Our study examined issues similar to those of previously conducted small-scale US studies of patients switching from insulin glargine to insulin detemir [15, 16] . However, the major strengths of our study compared to previous studies included that we examined a much larger study population from two independent cohorts, and that stringent PSM was used to balance the baseline characteristics of patients, thereby reducing potential confounders when interpreting results. Overall, the findings of this study support the use of insulin glargine, whether through continuation or switching, and may call for a careful re-examination of the therapeutic interchangeability of the two basal insulin analogs in the real-world setting. Indeed, these findings suggest that switching patients from insulin glargine to insulin detemir is more disruptive than switching patients from insulin detemir to insulin glargine. However, caution also needs to be exercised when interpreting these results due to the retrospective nature of this analysis.
CONCLUSION
In summary, the results from this study suggest that, in a real-world US managed care setting, switching patients with T2DM, including the elderly, from insulin detemir to insulin glargine, or maintaining patients on insulin glargine rather than switching to insulin detemir, may improve treatment persistence/ adherence and enhance glycemic outcomes. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.
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